Plasma D-dimer concentration in patients with systemic sclerosis.

Prior research has shown that elevated plasma D-dimer levels correlate with prothrombotic states in cardiovascular diseases. However, the relevance of D-dimer in systemic sclerosis remains unclear. Established knowledge indicates that systemic sclerosis involves vascular complications, but the role of D-dimer in this context is not well defined. No prior work had resolved whether D-dimer levels are consistently elevated in systemic sclerosis patients. This gap motivated a closer examination of D-dimer as a potential biomarker in this patient group. Previous studies suggest that D-dimer reflects fibrin turnover, but its clinical utility in systemic sclerosis is uncertain. The uncertainty around D-dimer's diagnostic value in this disease led to the current investigation. This study aims to clarify whether D-dimer levels can serve as a useful indicator in systemic sclerosis patients.

This study aimed to assess plasma D-dimer concentrations in patients with systemic sclerosis compared to healthy controls. The specific problem addressed is whether systemic sclerosis patients exhibit higher D-dimer levels than the general population. The motivation stems from the need to identify reliable biomarkers for vascular complications in this disease. The researchers sought to determine if D-dimer levels correlate with clinical features of systemic sclerosis. The study also aimed to explore whether high D-dimer levels are associated with macrovascular complications. The goal was to evaluate D-dimer as a potential tool for risk assessment in systemic sclerosis. The researchers hypothesized that elevated D-dimer levels might indicate an increased risk of thrombotic events. This investigation could improve early detection of vascular risks in systemic sclerosis patients.

The study involved measuring plasma D-dimer concentrations in 69 systemic sclerosis patients and 69 age- and sex-matched controls. Participants were selected consecutively to ensure a representative sample. Clinical and biological data were collected from all participants. Patients were categorized based on D-dimer levels above or equal to 500 ng/mL. Comparisons were made between patients with high D-dimer and those without. Vascular manifestations were assessed for each patient group. Statistical analysis was used to compare D-dimer levels between groups. The study focused on macrovascular complications such as peripheral ischaemia.

Median plasma D-dimer concentrations were significantly higher in systemic sclerosis patients than in controls (506 vs. 211 ng/mL; P<0.001). A high D-dimer concentration (≥500 ng/mL) was observed in 47.8% of systemic sclerosis patients. In contrast, only 4.5% of controls had D-dimer levels above this threshold. The difference between the two groups was statistically significant (P<0.0001). Macrovascular impairment was more common in patients with high D-dimer levels (21% vs. 6%; P=0.05). These findings suggest a potential link between elevated D-dimer and vascular complications. The association between D-dimer and macrovascular involvement is a novel observation. These results indicate that D-dimer may be a useful biomarker in systemic sclerosis.

The authors suggest that elevated D-dimer levels may help identify systemic sclerosis patients at risk for thrombotic complications. They propose that D-dimer could serve as an additional diagnostic tool in this patient population. The study highlights the potential clinical relevance of D-dimer in systemic sclerosis. The findings indicate that D-dimer levels correlate with macrovascular complications. The researchers emphasize the need for close monitoring of vascular parameters in patients with high D-dimer. These results support further investigation into D-dimer's role in systemic sclerosis. The authors note that the association between D-dimer and macrovascular involvement is an innovative finding. They recommend considering D-dimer testing for risk stratification in systemic sclerosis patients.